Request Legal Help Now - Free

Advertisement
LAWSUITS NEWS & LEGAL INFORMATION

FDA Reviews Saxagliptin (Onglyza and Kombiglyze XR) For Heart Failure Risk



Washington, DC: The Food and Drug Administration (FDA) has requested clinical trial data from the manufacturer of saxagliptin to investigate a possible association between use of the type 2 diabetes drug and heart failure.

The request resulted from a study published in the New England Journal of Medicine (NEJM), which reported an increased rate of hospitalization for heart failure, when the heart does not pump blood well enough, with use of saxagliptin (marketed as Onglyza and Kombiglyze XR) compared to an inactive treatment.

The study did not find increased rates of death or other major cardiovascular risks, including heart attack or stroke, in patients who received saxagliptin. The manufacturer is expected to submit the trial data to the FDA by early March 2014, after which the FDA will conduct a thorough analysis and report findings publicly.

At this time, the FDA considers information from the NEJM study to be preliminary. Analysis of the saxagliptin clinical trial data is part of a broader evaluation of, all type 2 diabetes drug therapies and cardiovascular risk.

Saxagliptin is used along with diet and exercise to lower blood sugar in adults with type 2 diabetes. It works by increasing the amount of insulin produced by the body after meals, when blood sugar is high.



Legal Help

If you or a loved one has suffered similar damages or injuries, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Last updated on

DIABETES MEDICATION SIDE EFFECTS LEGAL ARTICLES AND INTERVIEWS

Ozempic MDL and Semaglutide Update
Ozempic MDL and Semaglutide Update
March 15, 2024
Fifty-five Ozempic and similar weight loss drug lawsuits have been centralized in Eastern Pennsylvania, with U.S. District Judge Gene E.K. Pratter at the helm of the MDL and scheduled to commence March 14 at the first status conference. The litigation claims that Novo Nordisk's Ozempic, Wegovy and Rybelsus and Eli Lilly's Mounjaro and Trulicity cause gastroparesis and other serious gastrointestinal injuries, and the companies failed to warn patients about the risks associated with GLP-1 receptor agonist medications. READ MORE

Lawsuits Allege Ozempic Caused Gastroparesis; Do You Have A Claim?
Lawsuits Allege Ozempic Caused Gastroparesis; Do You Have A Claim?
March 8, 2024
 As the demand for Ozempic and other semaglutide weight-loss drugs increases, more serious side effects such as stomach paralysis are being reported to medical professionals, the FDA, and attorneys. READ MORE

Weight Loss Drugmakers Face Stomach Paralysis Lawsuits
Weight Loss Drugmakers Face Stomach Paralysis Lawsuits
January 27, 2024
A drugmaker’s dream is a patient continuing treatment and forever refilling prescriptions--and that spells profit.  Such is the case with the weight loss drugs because discontinuing them leads to regaining lost weight. Ozempic, Mounjaro and Wegovy are star performers, but a drugmaker’s nightmare is the serious side effects that leads to lawsuits, particularly when the manufacturers failed to disclose potential long-term impacts of serious injuries such as gastroparesis. READ MORE

ADD YOUR COMMENT ON THIS ISSUE

Please read our comment guidelines before posting.


Note: Your name will be published with your comment.


Your email will only be used if a response is needed.

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free